Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay).

BMC Clinical Pharmacology Pub Date : 2006-10-24 DOI:10.1186/1472-6904-6-8

Tanmay S Panchabhai, Shaun F Noronha, Sanish Davis, Vishal M Shinde, Nilima A Kshirsagar, Nithya J Gogtay

{"title":"Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay).","authors":"Tanmay S Panchabhai, Shaun F Noronha, Sanish Davis, Vishal M Shinde, Nilima A Kshirsagar, Nithya J Gogtay","doi":"10.1186/1472-6904-6-8","DOIUrl":null,"url":null,"abstract":"Background: Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).Methods: All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.Results: It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).Conclusion: A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.","PeriodicalId":9196,"journal":{"name":"BMC Clinical Pharmacology","volume":"6 ","pages":"8"},"PeriodicalIF":0.0000,"publicationDate":"2006-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1472-6904-6-8","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1472-6904-6-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 16

Abstract

Background: Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).

Methods: All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.

Results: It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).

Conclusion: A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

居住在孟买(Bombay)的古吉拉特邦和马尔瓦迪人CYP2C19活性的评价。

背景:药物代谢和处置的遗传差异，以及药物治疗靶点(如受体)的遗传多态性，可以极大地影响药物的疗效和毒性。CYP2C19(细胞色素P-450酶超家族的一员，催化I期药物代谢)的显着种族差异影响了许多临床重要药物的代谢。本研究通过表型分析(西印度人群)评估了正常、健康的古吉拉特邦和马尔瓦迪人CYP2C19的活性。方法:所有受试者均给予奥美拉唑20 mg，于3 h采血，测定奥美拉唑与5-羟基奥美拉唑的代谢比。HPLC法分析。结果:该人群中有10.36%为贫代谢者(PM)， 89.63%为广代谢者(EM)。结论:基因分型评价能更好地识别人群特异性基因型，从而有助于个体化药物治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Clinical Pharmacology

自引率

0.00%

发文量